6 March 2018 - Lonsurf, a new important treatment option for adult patients with metastatic colorectal cancer that has been shown to extend overall survival, represents the first Health Canada approved product for Taiho Group.

Taiho Pharmaceutical today announced that Health Canada, a Canadian healthcare authority, approved Lonsulf (trifluridine/tipiracil) for the treatment of adult patients with metastatic colorectal cancer (mCRC) who have been previously treated with, or are not candidates for, available therapies including fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapies, anti-VEGF biological agents, and, if RAS wild-type, anti-EGFR agents.

The Health Canada approval of Lonsulf is based on results from the global Phase III RECOURSE trial in 800 patients who have been previously treated for mCRC. The trial met the primary efficacy endpoint of statistically significant improvement in overall survival compared to placebo (HR = 0.68, p < 0.001) and demonstrated a safety profile consistent with that observed in earlier clinical trials.

Read Taiho Pharma press release